A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
← catalyst calendarSponsored by MediWound Ltd (industry) · MDWD — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
32estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-06-30 | actual | When the study began enrolling |
| Primary completion | May 2022 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2022 | estimated | The whole study's end, after follow-up |
| First posted | 2021-12-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2021-12-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Superficial Basal Cell Carcinoma
- Nodular Basal Cell Carcinoma
Intervention
- Drug: EscharEx 5% (EX-02 formulation) — also filed as EX-02 5%
Primary outcomes
what the primary-completion date above is the date OFIncidence and severity of treatment-emergent AEs (TEAEs) and serious TEAEs (STEAEs).
measured Through study completion - an average of 16 weeks
Vital signs - proportion of patients with abnormal clinical significant measurements
measured Up to completion of treatment period - up to 5 weeks
Pain assessments- Proportion of patients with clinical significant elevation in NPRS score
measured Up to completion of treatment period - up to 5 weeks
Proportion of subjects discontinuing a treatment due to TEAEs, assessed over the entire course of the treatment.
measured Up to completion of treatment period - up to 5 weeks
Proportion of subjects that requested to discontinue the treatment
measured Up to completion of treatment period - up to 5 weeks
Permalink · MDWD's whole pipeline · Catalyst calendar · Every registered study · What changed